• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
      • Cardiac Safety IconCardiac Solutions
        • Cardiac Solutions

          Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Arrhythmia Analysis

          Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Blood Pressure Services

          Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • ECG — On-site to DCT and Phase I-IV

          Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Phase I/TQT Cardiac Assessment

          Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Regulatory Consultation and Statistical Analysis Expertise

          Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

      • Clinical Adjudication
      • ECOA IconeCOA
        • eCOA Clinical Trials

          Make your clinical trials easier, faster, more engaging and accessible to all.

        • eCOA Live

          Enjoy flexible, fast and confidential site assessments at home.

        • eCOA Multimedia

          Enhance your ePRO data with photo and audio capture.

        • eCOA Rapid Start

          Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • eCOA Rater and Participant Training

          Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • eCOA Rescue Studies

          Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Suicidal Ideation

          Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

      • Medical ImagingMedical Imaging
        • Medical Imaging

          Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • Medical Imaging science team

          The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Image Redact AI

          Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Imaging Platform

          Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Modalities

          Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • SMART Submit

          Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

      • Precision Motion IconPrecision Motion
        • Precision Motion for Clinical Trials

          Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • Precision Motion for Research

          The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Precision Motion: Scientific Publications

          Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

      • Respiratory Solutions IconRespiratory
        • Respiratory Solutions

          Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Site-Based Spirometry (FEV1, FVC, PEF, and more.)

          Centralized, on-site pulmonary function testing for clinical trials.

        • Virtual Home Spirometry

          Remote spirometry testing for respiratory clinical trials.

        • Cough and Lung Sounds

          Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Diffusing Capacity (DLCO)

          Assess the capacity of the lungs for effective gas transfer.

      • Trial Enablement IconTrial Enablement
        • Trial Enablement

          Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Eligibility Solution

          Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Reporting & Analytics

          Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Source Document Manager

          Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
      • Biotechs
      • CROs
      • Pharmacist Icon RGBPharma
    • Study Phases
      • Safety Icon RGBPhase I
      • Clinical Trial Management System Icon RGBPhase II/III
    • Technology
      • AI Icon RGBArtificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rapid Start
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Solutions
      • Cardiac Solutions
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Imaging Platform
      • Modalities
      • SMART Submit
    • Precision Motion
      • Precision Motion for Clinical Trials
      • Precision Motion for Research
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, and more.)
      • Virtual Home Spirometry
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Hybrid Trials
    • Biotechs
    • CROs
    • Pharma
    • Phase I
    • Phase II/III
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology
    • Ophthalmology
    • Type 2 Diabetes and Obesity
    • Respiratory Solutions
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles eCOA vs. paper

eCOA vs. paper

Which should I use for my upcoming trial?

Valdo Arnera, M.D. – eCOA Scientific Advisor

We recently discussed the basics of eCOA and how it improves clinical trial data quality. For example, when compared to paper-based assessments, eCOA eliminates inconsistent data, increases patient compliance, is preferred by patients and recommended by regulatory agencies.1-4

In most cases, it is recommended to use eCOA; however, there are scenarios when paper may be considered. In this piece, we discuss occasions where the use of eCOA for capturing patient data is critical versus when it is recommended and how sponsors can reap the many benefits electronic data capture provides.

When is it critical to use eCOA?

“There are several scenarios when it is critical to capture your endpoint data electronically rather than on paper.”

Valdo Arnera, M.D. – eCOA Scientific Advisor

Valdo Arnera headshot

These scenarios include:

  • Questionnaires and/or daily diaries which are supporting primary endpoints: eCOA should be used when the success of your trial resides on the collection of patient diaries, as electronic assessments deliver significantly higher-quality data and more accurate results than paper data collection.
  • Questionnaires that don’t support primary endpoints but are unsupervised: Without the supervision of a healthcare professional, patients may procrastinate, inaccurately record, or forget to record entries in their questionnaire. Electronic assessments are designed to minimize or eliminate these problems through:
    • Alarms that are programmed to remind patients to complete their questionnaires appropriately
    • Software that prevents back and forward filling
    • Real-time reporting that automatically alerts sites when patient compliance is below a set threshold, allowing sites to intervene when necessary
  • Monitoring for Suicidal Ideation and Behavior (SIB): Sites must know in real-time if a patient is experiencing suicidal thoughts. Electronic tools, such as the self-reported electronic Columbia Suicide Severity Rating Scale (eC-SSRS) or the interviewer-rated C-SSRS, can achieve this level of urgency. The patient-reported version of the C-SSRS provides increased patient honesty, reduces rater variability, and allows real-time suicide risk notification.
  • Integrating data from another source: If patients inaccurately record or forget to record meter values from other devices like glucometers, eCOA features such as automatic data transfer and reminders offer an added layer of support.
  • Complex ClinROs: Complex calculations and scoring are error-prone and can be eliminated with automatic calculations. An example here would be the Psoriasis Area Severity Index [PASI].
  • Rare disease studies: These cases often have few participants in the study. It’s therefore essential to minimize missing and incomplete data.

When is it recommended to use eCOA?

To reduce burden and receive consistent, high-quality data, we also recommend using eCOA in the following scenarios:

  • Oncology trials: Regulators recommend using eCOA in oncology trials5 and are now requesting additional information about drug efficacy beyond survival, such as quality of life (e.g., symptom relief).
  • Large-scale studies: Errors incurred when using paper can result in significant delays and costs due to data cleansing and processing. This is especially true when working across diverse populations and in multiple countries.

In addition to these scenarios, there are several other key factors that underscore the advantages of eCOA. One of these is its ability to minimize data variability and enhance reliability. For example, a study by Merck Research Laboratories found that using electronic Patient-Reported Outcomes (ePRO) led to a 41% reduction in standard deviation compared to paper-based methods, resulting in more precise and higher-quality data. Read the full case study here.

When can paper be considered?

Aside from the scenarios mentioned above, there may be a small number of instances where sponsors could consider using paper. In the following three scenarios, paper may be an appropriate option.

  • Studies with a very small patient population: The financial cost of incorporating eCOA may be greater than the burden of collecting data manually.
  • Long-duration studies with infrequent questionnaire collection: the cost of deploying eCOA may make paper a more appropriate option.
  • Phase 1 studies: For example, in a trial taking place on-site over a single day with a group of healthy volunteers, the likelihood of non-compliance using paper is low.

Prior to using paper in these scenarios, the risks outlined above should be carefully considered and we strongly recommend you speak to our scientific advisors.

Summary

It is important to understand when it is critical to use electronic Clinical Outcome Assessments and the immense benefits eCOA brings with it over paper-based data capture. Our Clario Science team is on hand to offer advice on which method is most appropriate for your trial. Contact our team of experts or visit our Science page for further information.


References

1 Food and Drug Administration, FDA. 2009. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.
2 Food and Drug Administration, FDA. 2010. Guidance for Industry: Electronic Source Documentation in Clinical Investigations.
3 EMEA, 2005. Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products.
4 EMA 2014, Reflection Paper on the use of patient reported outcome 5 (PRO) measures in oncology studies
5 Food and Drug Administration, FDA. 2018. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, Guidance for Industry

To discuss using electronic data capture for your next study, contact our Science Team or visit our Science page.

Speak to a Scientist
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Researcher spotlight: Dr. Lauren Tueth

Precision Motion

Read
Article

Researcher spotlight: Brice Cleland

Precision Motion

Read
Article

Researcher spotlight: Josefa Domingos

Precision Motion

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum